BioTelemetry (BEAT) Stock Rating Upgraded by BidaskClub

BioTelemetry (NASDAQ:BEAT) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday.

Several other equities analysts have also commented on the company. TheStreet lowered BioTelemetry from a “b-” rating to a “c” rating in a research report on Tuesday, March 20th. Dougherty & Co reissued a “buy” rating and set a $41.00 price objective (up previously from $40.00) on shares of BioTelemetry in a research report on Friday, February 23rd. Finally, Zacks Investment Research lowered BioTelemetry from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. BioTelemetry currently has a consensus rating of “Buy” and an average target price of $43.00.

How to Become a New Pot Stock Millionaire

Shares of BioTelemetry stock opened at $34.40 on Tuesday. The company has a quick ratio of 1.66, a current ratio of 1.77 and a debt-to-equity ratio of 0.80. The firm has a market cap of $1,106.15, a price-to-earnings ratio of 35.46, a PEG ratio of 1.70 and a beta of 0.86. BioTelemetry has a 12 month low of $23.30 and a 12 month high of $39.20.

BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings data on Thursday, February 22nd. The medical research company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.24 by $0.08. The business had revenue of $91.70 million during the quarter, compared to analyst estimates of $88.33 million. BioTelemetry had a positive return on equity of 14.54% and a negative net margin of 5.56%. The company’s revenue for the quarter was up 69.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.23 earnings per share. sell-side analysts anticipate that BioTelemetry will post 1.25 EPS for the current year.

In other news, insider Fred Broadway sold 54,158 shares of the firm’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $34.17, for a total transaction of $1,850,578.86. Following the completion of the transaction, the insider now directly owns 64,880 shares in the company, valued at $2,216,949.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.30% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the company. First Dallas Securities Inc. bought a new position in shares of BioTelemetry during the fourth quarter valued at $133,000. Landscape Capital Management L.L.C. bought a new position in shares of BioTelemetry during the fourth quarter valued at $248,000. Macquarie Group Ltd. bought a new position in shares of BioTelemetry during the third quarter valued at $279,000. Teacher Retirement System of Texas bought a new stake in BioTelemetry in the 4th quarter worth about $297,000. Finally, Campbell Newman Asset Management Inc. increased its holdings in BioTelemetry by 21.5% in the 4th quarter. Campbell Newman Asset Management Inc. now owns 10,134 shares of the medical research company’s stock worth $303,000 after buying an additional 1,796 shares in the last quarter. Hedge funds and other institutional investors own 87.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BioTelemetry (BEAT) Stock Rating Upgraded by BidaskClub” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2018/04/17/biotelemetry-beat-stock-rating-upgraded-by-bidaskclub.html.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply